Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PAVmed (PAVM) EBITDA (2016 - 2025)

PAVmed has reported EBITDA over the past 5 years, most recently at -$6.8 million for Q4 2025.

  • For Q4 2025, EBITDA fell 31.15% year-over-year to -$6.8 million; the TTM value through Dec 2025 reached -$21.8 million, up 55.76%, while the annual FY2025 figure was -$21.8 million, 50.98% up from the prior year.
  • EBITDA for Q4 2025 was -$6.8 million at PAVmed, down from -$4.8 million in the prior quarter.
  • Over five years, EBITDA peaked at -$4.7 million in Q2 2025 and troughed at -$24.6 million in Q4 2022.
  • A 5-year average of -$14.2 million and a median of -$14.0 million in 2024 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: crashed 143.1% in 2022 and later surged 68.34% in 2024.
  • Year by year, EBITDA stood at -$19.7 million in 2021, then dropped by 25.01% to -$24.6 million in 2022, then surged by 33.41% to -$16.4 million in 2023, then surged by 68.34% to -$5.2 million in 2024, then plummeted by 31.15% to -$6.8 million in 2025.
  • Business Quant data shows EBITDA for PAVM at -$6.8 million in Q4 2025, -$4.8 million in Q3 2025, and -$4.7 million in Q2 2025.